Syed Ahmed Zaki1, Sunil Karande. 1. Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India. drzakisyed@gmail.com
Abstract
INTRODUCTION: Multidrug-resistant typhoid fever (MDRTF) is defined as typhoid fever caused by Salmonella enterica serovar Typhi strains (S. Typhi), which are resistant to the first-line recommended drugs for treatment such as chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole. Since the mid-1980s, MDRTF has caused outbreaks in several countries in the developing world, resulting in increased morbidity and mortality, especially in affected children below five years of age and those who are malnourished. METHODOLOGY: Two methods were used to gather the information presented in this article. First PubMed was searched for English language references to published relevant articles. Secondly, chapters on typhoid fever in standard textbooks of paediatric infectious diseases and preventive and social medicine were reviewed. RESULTS: Although there are no pathognomonic clinical features of MDRTF at the onset of the illness, high fever ( > 104°F), toxaemia, abdominal distension, abdominal tenderness, hepatomegaly and splenomegaly are often reported. The gold standard for the diagnosis of MDRTF is bacterial isolation of the organism in blood cultures. Ciprofloxacin and ceftriaxone are the drugs most commonly used for treatment of MDRTF and produce good clinical results. CONCLUSION: MDRTF remains a major public health problem, particularly in developing countries. Mass immunization in endemic areas with either the oral live attenuated Typhi 21a or the injectable unconjugated Vi typhoid vaccine, rational use of antibiotics, improvement in public sanitation facilities, availability of clean drinking water, promotion of safe food handling practices and public health education are vital in the prevention of MDRTF.
INTRODUCTION: Multidrug-resistant typhoid fever (MDRTF) is defined as typhoid fever caused by Salmonella enterica serovar Typhi strains (S. Typhi), which are resistant to the first-line recommended drugs for treatment such as chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole. Since the mid-1980s, MDRTF has caused outbreaks in several countries in the developing world, resulting in increased morbidity and mortality, especially in affected children below five years of age and those who are malnourished. METHODOLOGY: Two methods were used to gather the information presented in this article. First PubMed was searched for English language references to published relevant articles. Secondly, chapters on typhoid fever in standard textbooks of paediatric infectious diseases and preventive and social medicine were reviewed. RESULTS: Although there are no pathognomonic clinical features of MDRTF at the onset of the illness, high fever ( > 104°F), toxaemia, abdominal distension, abdominal tenderness, hepatomegaly and splenomegaly are often reported. The gold standard for the diagnosis of MDRTF is bacterial isolation of the organism in blood cultures. Ciprofloxacin and ceftriaxone are the drugs most commonly used for treatment of MDRTF and produce good clinical results. CONCLUSION: MDRTF remains a major public health problem, particularly in developing countries. Mass immunization in endemic areas with either the oral live attenuated Typhi 21a or the injectable unconjugated Vi typhoid vaccine, rational use of antibiotics, improvement in public sanitation facilities, availability of clean drinking water, promotion of safe food handling practices and public health education are vital in the prevention of MDRTF.
Authors: Rene S Hendriksen; Pimlapas Leekitcharoenphon; Oksana Lukjancenko; Chileshe Lukwesa-Musyani; Bushimbwa Tambatamba; John Mwaba; Annie Kalonda; Ruth Nakazwe; Geoffrey Kwenda; Jacob Dyring Jensen; Christina A Svendsen; Karen K Dittmann; Rolf S Kaas; Lina M Cavaco; Frank M Aarestrup; Henrik Hasman; James C L Mwansa Journal: J Clin Microbiol Date: 2014-11-12 Impact factor: 5.948
Authors: Ky V Hoang; Hassan M Borteh; Murugesan V S Rajaram; Kevin J Peine; Heather Curry; Michael A Collier; Michael L Homsy; Eric M Bachelder; John S Gunn; Larry S Schlesinger; Kristy M Ainslie Journal: Int J Pharm Date: 2014-10-22 Impact factor: 5.875
Authors: Matt Maybeno; Anke Redeker; Suzanne P M Welten; Bjoern Peters; Scott M Loughhead; Stephen P Schoenberger; Alessandro Sette; Ramon Arens Journal: PLoS One Date: 2012-08-17 Impact factor: 3.240
Authors: Karin Leder; Joseph Torresi; Michael D Libman; Jakob P Cramer; Francesco Castelli; Patricia Schlagenhauf; Annelies Wilder-Smith; Mary E Wilson; Jay S Keystone; Eli Schwartz; Elizabeth D Barnett; Frank von Sonnenburg; John S Brownstein; Allen C Cheng; Mark J Sotir; Douglas H Esposito; David O Freedman Journal: Ann Intern Med Date: 2013-03-19 Impact factor: 25.391